CD8A and neoplasm: While continuous efforts towards the clinical applications of CD8+ T cell-based therapeutics are doubtlessly necessitated, the fundamental understanding of both tumor and T-cell biology, such as tumor heterogeneity and checkpoint blockade, to better design the immunotherapy regimen and to assess therapeutic outcome, is greatly warranted.